Recent Updates
Recently added Catalysts
VNDA

Vanda Pharmaceuticals to Participate in UBS Global Life Sciences Conference

Key Takeaway: ROCKVILLE, Md., Sept. 14, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced that Mihael H. Polymeropoulos, M.D., Va

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+121%
120-day peak, hindsight
Typical move
19.9%
average across 7 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
Imsidolimab
Phase 2 · Palmoplantar Pustulosis

Full Press Release Details

ROCKVILLE, Md., Sept. 14, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced that Mihael H. Polymeropoulos, M.D., Vanda's President and CEO will deliver a corporate presentation at the UBS Global Life Sciences Conference in New York City on Tuesday, September 20, 2011 at 12:30 p.m. Eastern Time.
Dr. Polymeropoulos' presentation at the UBS Global Life Sciences Conference will be available live on Vanda's corporate website, where it also will be archived for 30 days. To access the presentation, log on to http://www.vandapharma.com and click on the Presentations option in the Investor Relations section. Please connect to the website several minutes prior to the start of the live presentation.
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.
Communications Manager
Vanda Pharmaceuticals Inc.
Last updated: Sep 14, 2011